References
- Imberti D, Vallisa D, Anselmi E, et al. Safety and efficacy of enoxaparin treatment in venous thromboembolic disease during acute leukemia. Tumori 2004;90:390–393.
- Herishanu Y, Misgav M, Kirgner I, et al. Enoxaparin can be used safely in patients with severe thrombocytopenia due to intensive chemotherapy regimens. Leuk Lymphoma 2004;45:1407–1411.
- Common Terminology Criteria for Adverse Events v 4.0 (CTCAE). Published to NCI website on May 28, 2009. Bethesda, MD: National Cancer Institute. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm
- Blom JW, Doggen CJ, Osanto S, et al. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293: 715–722.
- Ku GH, White RH, Chew HK, et al. Venous thromboembolism in patients with acute leukemia: incidence, risk factors, and effect on survival. Blood 2009;113:3911–3917.
- Grisariu S, Spectre G, Kalish Y, et al. Increased risk of central venous catheter-associated thrombosis in acute promyelocytic leukemia: a single-institution experience. Eur J Haematol 2013;90:397–403.
- Melillo L, Grandone E, Colaizzo D, et al. Symptomatic venous thromboembolism and thrombophilic status in adult acute leukemia: a single-center experience of 114 patients at diagnosis. Acta Haematol 2007;117:215–220.
- De Stefano V, Sora F, Rossi E, et al. The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. J Thromb Haemost 2005;3:1985–1992.
- Chopra V, Ratz D, Kuhn L, et al. Peripherally inserted central catheter-related deep vein thrombosis: contemporary patterns and predictors. J Thromb Haemost 2014;12:847–854.
- Verso M, Agnelli G. Venous thromboembolism associated with long-term use of central venous catheters in cancer patients. J Clin Oncol 2003;21:3665–3675.
- Lee AY, Levine MN, Butler G, et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol 2006;24:1404–1408.
- Mohren M, Markmann I, Jentsch-Ullrich K, et al. Increased risk of venous thromboembolism in patients with acute leukaemia. Br J Cancer 2006;94:200–202.
- Boersma RS, Jie KS, Verbon A, et al. Thrombotic and infectious complications of central venous catheters in patients with hematological malignancies. Ann Oncol 2008;19:433–442.
- van Rooden CJ, Rosendaal FR, Barge RM, et al. Central venous catheter related thrombosis in haematology patients and prediction of risk by screening with Doppler-ultrasound. Br J Haematol 2003;123: 507–512.
- Lazo-Langner A, Goss GD, Spaans JN, et al. The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost 2007;5:729–737.
- Nagy Z, Turcsik V, Blasko G. The effect of LMWH (nadroparin) on tumor progression. Pathol Oncol Res 2009;15:689–692.
- Wildhagen KC, Garcia de Frutos P, Reutelingsperger CP, et al. Nonanticoagulant heparin prevents histone-mediated cytotoxicity in vitro and improves survival in sepsis. Blood 2014;123:1098–1101.
- Falanga A, Rickles FR. Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost 1999;25:173–182.
- Dong X, Shi J, Zhou J, et al. Chemotherapy induces enhanced procoagulant activity through phosphatidylserine exposure in acute lymphoblastic leukemia. Thromb Res 2013;132:614–620.
- Kulkarni KP. L-Asparaginase induced thrombosis in acute lymphoblastic leukemia. J Pharmacol Pharmacother 2012;3:285–286.
- Ranta S, Heyman MM, Jahnukainen K, et al. Antithrombin deficiency after prolonged asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis 2013;24: 749–756.